These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 26538238)

  • 21. Regulation of signal transduction by reactive oxygen species in the cardiovascular system.
    Brown DI; Griendling KK
    Circ Res; 2015 Jan; 116(3):531-49. PubMed ID: 25634975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of testosterone therapy in hypogonadal patients and its controversial adverse impact on the cardiovascular system.
    Kharaba ZJ; Buabeid MA; Alfoteih YA
    Crit Rev Toxicol; 2020 Jul; 50(6):491-512. PubMed ID: 32689855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Androgens and cardiovascular risk: A series of case report in the French and Canadian pharmacovigilance databases].
    Rochoy M; Thomas R; Béné J; Deleplanque D; Vantyghem MC; Gautier S; Deplanque D;
    Prog Urol; 2018 May; 28(6):315-321. PubMed ID: 29650456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testosterone therapy and cardiovascular risk.
    Walsh JP; Kitchens AC
    Trends Cardiovasc Med; 2015 Apr; 25(3):250-7. PubMed ID: 25467243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond the male sex hormone: deciphering the metabolic and vascular actions of testosterone.
    Kang HY
    J Endocrinol; 2013 Jun; 217(3):C1-3. PubMed ID: 23528478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelins and NADPH oxidases in the cardiovascular system.
    Dammanahalli KJ; Sun Z
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):2-6. PubMed ID: 18047620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New opportunities for targeting redox dysregulation in cardiovascular disease.
    Bubb KJ; Drummond GR; Figtree GA
    Cardiovasc Res; 2020 Mar; 116(3):532-544. PubMed ID: 31297507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reactive oxygen species and the cardiovascular system.
    Taverne YJ; Bogers AJ; Duncker DJ; Merkus D
    Oxid Med Cell Longev; 2013; 2013():862423. PubMed ID: 23738043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transmitting biological information using oxygen: reactive oxygen species as signalling molecules in cardiovascular pathophysiology.
    Shah AM; Sauer H
    Cardiovasc Res; 2006 Jul; 71(2):191-4. PubMed ID: 16781690
    [No Abstract]   [Full Text] [Related]  

  • 30. Controversy over Cardiovascular Risks of Testosterone Therapy.
    Carter D
    Am J Nurs; 2015 May; 115(5):17. PubMed ID: 25906216
    [No Abstract]   [Full Text] [Related]  

  • 31. Beneficial and adverse effects of testosterone on the cardiovascular system in men.
    Ruige JB; Ouwens DM; Kaufman JM
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4300-10. PubMed ID: 24064693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testosterone deficiency as a risk factor for cardiovascular disease.
    Ullah MI; Washington T; Kazi M; Tamanna S; Koch CA
    Horm Metab Res; 2011 Mar; 43(3):153-64. PubMed ID: 21283952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Controversies in testosterone replacement therapy: testosterone and cardiovascular disease.
    Hwang K; Miner M
    Asian J Androl; 2015; 17(2):187-91. PubMed ID: 25652628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism.
    Miller KK; Biller BM; Schaub A; Pulaski-Liebert K; Bradwin G; Rifai N; Klibanski A
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2474-9. PubMed ID: 17426086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Why is understanding the relationship of testosterone to cardiovascular risk so important?
    Yeap BB; Anawalt BD
    Asian J Androl; 2018; 20(2):107-108. PubMed ID: 29405170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological approaches to the treatment of oxidative stress-induced cardiovascular dysfunctions.
    Zamora PL; Villamena FA
    Future Med Chem; 2013 Mar; 5(4):465-78. PubMed ID: 23495692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of androgens on the cardiovascular system.
    Rosano GM; Cornoldi A; Fini M
    J Endocrinol Invest; 2005; 28(3 Suppl):32-8. PubMed ID: 16042358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgens and coronary artery disease.
    Wu FC; von Eckardstein A
    Endocr Rev; 2003 Apr; 24(2):183-217. PubMed ID: 12700179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editor's Comment--How Dangerous is Testosterone Supplementation?
    Jenkins LC; Mulhall JP
    Int Braz J Urol; 2015; 41(2):195-8. PubMed ID: 26005958
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety of estrogen/androgen regimens.
    Simon JA
    J Reprod Med; 2001 Mar; 46(3 Suppl):281-90. PubMed ID: 11304876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.